Efficacy and safety of sorafenib combined with transarterial chemoembolization in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
029 patients met the inclusion criteria for this meta-analysis, including sorafenib combined with TACE group (n=1023) and TACE group (n=1006).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, no significant difference was found in nausea or vomit [OR = 1.14,95%CI (0.81,1.59), P = 0.68] or fever [OR = 0.87, 95%CI (0.61,1.23), P = 0.87]. [CONCLUSION] The current comprehensive evidence suggests that sorafenib combined with TACE is more effective than TACE alone, especially for patients with intermediate-advanced and primary HCC.
[OBJECTIVE] Transarterial chemoembolization (TACE) plus sorafenib has led to an increase in randomized controlled trials The efficacy and safety of sorafenib combined with TACE for the treatment of he
- 표본수 (n) 1023
- p-value P < 0.00001
- OR 1.58
- 연구 설계 meta-analysis
APA
Yu L, Xiong Y, et al. (2025). Efficacy and safety of sorafenib combined with transarterial chemoembolization in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.. Frontiers in oncology, 15, 1640879. https://doi.org/10.3389/fonc.2025.1640879
MLA
Yu L, et al.. "Efficacy and safety of sorafenib combined with transarterial chemoembolization in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.." Frontiers in oncology, vol. 15, 2025, pp. 1640879.
PMID
41293272 ↗
Abstract 한글 요약
[OBJECTIVE] Transarterial chemoembolization (TACE) plus sorafenib has led to an increase in randomized controlled trials The efficacy and safety of sorafenib combined with TACE for the treatment of hepatocellular carcinoma (HCC) remain controversial. We conducted a comprehensive meta-analysis of randomized controlled trials on this issue.
[METHODS] A literature search was conducted by using online database: PubMed, the Cochrane Library, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI) and Wan-fang, with no language restrictions. A Meta-analysis was performed to calculate the pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) for the efficacy and safety of sorafenib combined with TACE in the treatment of HCC. Review Manager 5.4 software was used for data analysis.
[RESULTS] A total of 19 randomized controlled trials involving 2,029 patients met the inclusion criteria for this meta-analysis, including sorafenib combined with TACE group (n=1023) and TACE group (n=1006). The results of meta-analysis showed that sorafenib combined with TACE had a better prognosis in partial response rate (PR) [OR = 1.58,95%CI (1.30,1.92), P < 0.00001] with low heterogeneity among studies (P = 0.67; I2 = 0%) and the objective response rate (ORR) [OR = 1.93, 95%CI (1.59,2.34), P < 0.00001] with low heterogeneity among studies (P = 0.42; I2 = 3%). The 12-month overall survival (OS) was also significantly increased by combination therapy [OR = 3.18, 95%CI (2.41,4.19), P < 0.00001]. In terms of safety, the incidences were significantly high in TACE plus sorafenib group compared to TACE group for hand-foot skin reaction OR = 4.48, 95%CI (3.28,6.13), P < 0.00001 and for abdominal pain or diarrhea OR = 3.10, 95%CI (2.24,4.29), P = 0.04. However, no significant difference was found in nausea or vomit [OR = 1.14,95%CI (0.81,1.59), P = 0.68] or fever [OR = 0.87, 95%CI (0.61,1.23), P = 0.87].
[CONCLUSION] The current comprehensive evidence suggests that sorafenib combined with TACE is more effective than TACE alone, especially for patients with intermediate-advanced and primary HCC.
[METHODS] A literature search was conducted by using online database: PubMed, the Cochrane Library, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI) and Wan-fang, with no language restrictions. A Meta-analysis was performed to calculate the pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) for the efficacy and safety of sorafenib combined with TACE in the treatment of HCC. Review Manager 5.4 software was used for data analysis.
[RESULTS] A total of 19 randomized controlled trials involving 2,029 patients met the inclusion criteria for this meta-analysis, including sorafenib combined with TACE group (n=1023) and TACE group (n=1006). The results of meta-analysis showed that sorafenib combined with TACE had a better prognosis in partial response rate (PR) [OR = 1.58,95%CI (1.30,1.92), P < 0.00001] with low heterogeneity among studies (P = 0.67; I2 = 0%) and the objective response rate (ORR) [OR = 1.93, 95%CI (1.59,2.34), P < 0.00001] with low heterogeneity among studies (P = 0.42; I2 = 3%). The 12-month overall survival (OS) was also significantly increased by combination therapy [OR = 3.18, 95%CI (2.41,4.19), P < 0.00001]. In terms of safety, the incidences were significantly high in TACE plus sorafenib group compared to TACE group for hand-foot skin reaction OR = 4.48, 95%CI (3.28,6.13), P < 0.00001 and for abdominal pain or diarrhea OR = 3.10, 95%CI (2.24,4.29), P = 0.04. However, no significant difference was found in nausea or vomit [OR = 1.14,95%CI (0.81,1.59), P = 0.68] or fever [OR = 0.87, 95%CI (0.61,1.23), P = 0.87].
[CONCLUSION] The current comprehensive evidence suggests that sorafenib combined with TACE is more effective than TACE alone, especially for patients with intermediate-advanced and primary HCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Reinforced immunotherapy of M1 macrophage-derived exosomes with CEL on TNBC via regulating macrophage functions.
- Nuclear receptor subfamily 2 group F member 2 transcriptionally activates 14-3-3 epsilon to promote diffuse large B-cell lymphoma progression.
- Inflammation- and resolution-programmed myeloid circuits govern therapeutic resistance in epithelial and mesenchymal triple-negative breast cancer.
- Clinical characteristics, management, and prognosis of pembrolizumab-induced immune-related oral mucositis.
- Transformation of nanoparticles into hydrogels for long-acting and sensitized apoptosis therapy of triple negative breast cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Creative Arts Therapy for Anxiety, Depression, and Quality of Life in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.